Capricor Therapeutics (CAPR) shares were down nearly 49% pre-bell Friday after the company said that the US Food and Drug Administration has required additional clinical data on deramiocel, a cell therapy candidate for cardiomyopathy in Duchenne muscular dystrophy patients.
Q32 Bio (QTTB) shares were 31% lower, erasing part of Thursday's rally.
Concorde International (CIGL) stock was down 28%, extending Thursday's slide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.